

HIC1 (Hypermethylated in Cancer 1) modulates the contractile activity of prostate stromal fibroblasts and directly regulates *CXCL12* expression

SUPPLEMENTARY MATERIALS



Supplementary Figure 1: Control immunofluorescence analyses of WPMY-1 cells. WPMY-1 cells transfected with the indicated siRNAs were treated for 1 hour with Etoposide (20 mM) or with DMSO as control and fixed with paraformaldehyde. For each conditions cells were analyzed by conventional immunofluorescence microscopy using as primary antibody (ab I) either the monoclonal anti-HIC1 antibody (H-6) or an anti- γ H2AX antibody to monitor the induction of DNA damages and the relevant secondary antibodies (ab II) (Right columns: ab I + ab II). As controls, cells were also incubated with the secondary antibody alone (Left columns: ab II). Nuclei are seen as DAPI-positive staining. The merging of the two images is shown in the two bottom panels.

WPMY-1



Supplementary Figure 2: HIC1 binds the *CXCL12* promoter. Chromatin was prepared from BJ-hTERT cells and ChIP analyses were performed for HIC1 or IgG at a conserved HIC1 binding site in *CXCL12* promoter. P21 and GAPDH were used as a positive and nonbinding control, respectively. Values that are statistically different are indicated by bars and asterisks as follows: *P < 0.05 and ***P < 0.001. Values that are not statistically significantly different are also indicated (NS).

Supplementary Table 1: Clinical/pathological characteristics of the prostate tumors. See Supplementary Table 1

RT- qPCR		
HIC1 Total	Forward	CGACGACTACAAGAGCAGCAGC
HIC1 Total	Reverse	CAGGTTGTCACCGAAGCTCTC
HIC1 Variant 1	Forward	GACCAGCAGGACAGACCGA
HIC1 Variant 1	Reverse	TGGGGGGCATGTCGAAAG
CXCL12	Forward	AACGCCAAGGTCGTGGTC
CXCL12	Reverse	GCATGGGCATCTGTAGCTCA
GAPDH	Forward	GCACCGTCAAGGCTGAGAA
GAPDH	Reverse	CGCCCCACTTGATTTTGGA
TWIST	Forward	GCCTTCTCGGTCTGGAGGAT
TWIST	Reverse	TTCTCTGGAAACAATGACATCTAGG
SLUG	Forward	AAGGCGTTTTCCAGACCCTG
SLUG	Reverse	AAGAAAAAGGCTTCTCCCCCGT
α SMA	Forward	CTGTTTTCCCATCCATTGTG
α SMA	Reverse	CCATGTTCTATCGGGTACTT
188	Forward	GGCGCCCCTCGATGCTCTTAG
188	Reverse	GCTCGGGCCTGCTTTGAACACTCT
ALAS1	Forward	TGGTGCAGTAATGACTACCTAGGA
ALAS1	Reverse	CCCCAGCACCATGTTGTTT

Supplementary Table 2: Oligos used in the RT-qPCR experiments RT- qPCR